Spoken Alpha
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics develops oncolytic virus therapies designed to treat cancer. The company's RedTail platform uses engineered vaccinia viruses that survive in the bloodstream to reach metastatic tumors, replicate selectively in cancer cells, and deliver genetic medicines like IL-15 to tumor sites.
Calidi Biotherapeutics, Inc is a Healthcare company operating in Biotechnology with a $3.1M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add CLDI, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CLDI.
$ curl https://api.spokenalpha.com/v1/companies/CLDIFAQ
Spoken Alpha indexes CLDI's earnings call transcripts at https://spokenalpha.com/companies/CLDI. Each call links to attributed speakers and parsed analyst Q&A. Calidi Biotherapeutics, Inc.'s own investor relations page is at https://ir.calidibio.com/overview/default.aspx.
Calidi Biotherapeutics, Inc. (CLDI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-2.94 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-2.21 | $-1.68 | -31.6% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-1.99 | $-1.32 | -50.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-2.25 | $-1.80 | -25.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-0.27 | $-0.09 | -100.0% | $1.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-7.80 | $-10.26 | +24.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-16.80 | $-17.40 | +3.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-23.71 | $-32.40 | +26.8% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-14 | $-0.48 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-63.43 | $-20.40 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-29 | $-0.43 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $-27.02 | — | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.26 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $0.02 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $0.14 | $0.00 | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $0.05 | $0.00 | — | $45.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $0.15 | $0.00 | — | $405.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.03 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2021 | 2021-09-12 | $0.00 | $0.00 | — | — | — | — | EODHD |
Source: EODHD. CLDI reported actuals as published; sparse fields render as —.